Open AccessSafety and Efficacy of Natalizumab as Adjunctive Therapy for People With Drug-Resistant Epilepsy
Author(s) -
Jacqueline French,
Andrew J. Cole,
Edward Faught,
William H. Theodore,
Annamaria Vezzani,
Kore Liow,
Jonathan J. Halford,
Robert C. Armstrong,
Jerzy P. Szaflarski,
Susan M. Hubbard,
Jagdish Patel,
Kun Chen,
Weiwei Feng,
Marco Rizzo,
Jacob Elkins,
Gabrielle J. Knafler,
Kimberly A. Parkerson
Publication year - 2021
Publication title -
neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.91
H-Index - 364
eISSN - 1526-632X
pISSN - 0028-3878
DOI - 10.1212/wnl.0000000000012766
Subject(s) - natalizumab , medicine , placebo , adverse effect , randomized controlled trial , epilepsy , anesthesia , psychiatry , pathology , alternative medicine , disease
To explore efficacy/safety of natalizumab, a humanized monoclonal anti-α4-integrin antibody, as adjunctive therapy in adults with drug-resistant focal epilepsy.